Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$14.62 - $18.42 $2,587 - $3,260
-177 Reduced 1.38%
12,614 $204,000
Q1 2024

May 13, 2024

SELL
$17.79 - $30.86 $658 - $1,141
-37 Reduced 0.29%
12,791 $236,000
Q4 2023

Feb 13, 2024

BUY
$20.78 - $31.77 $415 - $635
20 Added 0.16%
12,828 $401,000
Q3 2023

Nov 13, 2023

BUY
$20.84 - $33.47 $562 - $903
27 Added 0.21%
12,808 $266,000
Q2 2023

Aug 10, 2023

SELL
$17.8 - $25.65 $1,406 - $2,026
-79 Reduced 0.61%
12,781 $306,000
Q1 2023

May 09, 2023

BUY
$16.32 - $20.92 $228 - $292
14 Added 0.11%
12,860 $242,000
Q4 2022

Feb 14, 2023

SELL
$14.2 - $18.63 $49,700 - $65,205
-3,500 Reduced 21.41%
12,846 $204,000
Q2 2022

Aug 05, 2022

BUY
$13.01 - $27.22 $6,505 - $13,610
500 Added 3.16%
16,346 $230,000
Q1 2022

May 02, 2022

BUY
$20.94 - $27.5 $20,940 - $27,500
1,000 Added 6.74%
15,846 $384,000
Q4 2021

Feb 11, 2022

SELL
$16.79 - $27.09 $220,855 - $356,341
-13,154 Reduced 46.98%
14,846 $347,000
Q3 2021

Nov 18, 2021

BUY
$15.78 - $24.77 $44,184 - $69,356
2,800 Added 11.11%
28,000 $465,000
Q1 2021

Apr 21, 2021

BUY
$25.02 - $54.99 $85,068 - $186,966
3,400 Added 15.6%
25,200 $650,000
Q3 2020

Nov 02, 2020

BUY
$36.42 - $57.0 $36,420 - $57,000
1,000 Added 4.81%
21,800 $1,000
Q2 2020

Aug 03, 2020

BUY
$39.26 - $52.73 $121,706 - $163,463
3,100 Added 17.51%
20,800 $1.01 Million
Q1 2020

Apr 30, 2020

BUY
$31.65 - $46.87 $256,365 - $379,647
8,100 Added 84.38%
17,700 $748,000
Q4 2019

Feb 13, 2020

BUY
$36.21 - $51.4 $347,616 - $493,440
9,600 New
9,600 $411,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Personal Cfo Solutions, LLC Portfolio

Follow Personal Cfo Solutions, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Personal Cfo Solutions, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Personal Cfo Solutions, LLC with notifications on news.